The BRAF (V600E) mutation analysis is predictive for anti-EGFR therapies (i.e., cetuximab and panitumumab). BRAF mutations account for approximately 12-15% of colorectal cancer patients.

V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog also known as KRAS is a protein which in humans is encoded by the KRAS gene. Like other members of the Ras family, the KRAS protein is a GTPase and is an early player in many signal transduction pathways. KRAS is usually tethered to cell membranes because of the presence of an isoprenyl group on its C-terminus.

Pulmotype provides pathologists with a valuable new tool to help their oncologist clients understand which patients are eligible for a number of new therapies now available for the treatment of NSCLC . Its ability to accurately sub-classify lung cancer will enable physicians to make much more informed and effective therapy decisions.